Related Experiment Videos
A randomized, open, comparative study of brodimoprim versus erythromycin in patients with acute tonsillitis or
1Kinderartz FMH, Basel, Switzerland.
Insights
Brodimoprim and erythromycin showed equal effectiveness in treating childhood acute tonsillitis and bronchitis. Both antibiotics were well-tolerated, with minor side effects reported in a small number of patients.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
Background:
- Acute tonsillitis and bronchitis are common childhood infections.
- Antibiotic therapy is a cornerstone in managing these conditions.
- Evaluating new or existing antibiotic options is crucial for optimizing treatment outcomes.
Purpose of the Study:
- To compare the efficacy and tolerability of brodimoprim versus erythromycin.
- To assess treatment success rates in children diagnosed with acute tonsillitis or bronchitis.
- To document and compare the incidence of adverse effects between the two antibiotic groups.
Main Methods:
- A comparative study involving 50 children aged 0.5 to 9.3 years.
- Participants were randomized into two groups, with 25 receiving brodimoprim and 25 receiving erythromycin.
- Therapeutic response was evaluated using clinical criteria.
Main Results:
- Both brodimoprim and erythromycin demonstrated high efficacy, with 24 out of 25 patients in each group showing a successful treatment outcome.
- One treatment failure was recorded in each antibiotic group.
- Adverse reactions were mild: three patients on brodimoprim experienced stomatitis, vomiting, or skin rash, while one patient on erythromycin developed a skin rash.
Conclusions:
- Brodimoprim and erythromycin are equally effective for treating acute tonsillitis and bronchitis in children.
- Both treatment regimens exhibited good tolerability with a low incidence of side effects.
- Clinical criteria are sufficient for evaluating the therapeutic response in these pediatric infections.
Unlabelled:
The objective of the study was the comparison of the efficacy and tolerability of brodimoprim to those of erythromycin in children with acute tonsillitis or bronchitis. 50 children aged 0.5 to 9.3 years were included in the study, 25 treated either with brodimoprim or with erythromycin. The evaluation of the therapeutic response was based exclusively on clinical criteria. In the brodimoprim group the therapy was successful in 24 patients (one failure), in the erythromycin group the therapy was also successful in 24 children (one failure). Side effects: three patients treated with brodimoprim reported adverse reactions (stomatitis, vomiting, skin rash), whereas only one patient in the erythromycin group developed a skin rash.
Conclusion:
both therapeutic regimens were equally effective against bronchitis and tonsillitis in children. The tolerability was good in both groups.